Prolonged antigen survival and cytosolic export in cross-presenting human γδ T cells
Human blood Vγ9Vδ2 T cells respond to signals from microbes and tumors and subsequently differentiate into professional antigen-presenting cells (γδ T-APCs) for induction of CD4⁺ and CD8⁺ T cell responses. γδ T-APCs readily take up and degrade exogenous soluble protein for peptide loading on MHC I,...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 107; no. 19; pp. 8730 - 8735 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
National Academy of Sciences
11.05.2010
National Acad Sciences |
Subjects | |
Online Access | Get full text |
ISSN | 0027-8424 1091-6490 |
DOI | 10.1073/pnas.1002769107 |
Cover
Summary: | Human blood Vγ9Vδ2 T cells respond to signals from microbes and tumors and subsequently differentiate into professional antigen-presenting cells (γδ T-APCs) for induction of CD4⁺ and CD8⁺ T cell responses. γδ T-APCs readily take up and degrade exogenous soluble protein for peptide loading on MHC I, in a process termed antigen cross-presentation. The mechanisms underlying antigen cross-presentation are ill-defined, most notably in human dendritic cells (DCs), and no study has addressed this process in γδ T-APCs. Here we show that intracellular protein degradation and endosomal acidification were significantly delayed in γδ T-APCs compared with human monocyte-derived DCs (moDCs). Such conditions are known to favor antigen cross-presentation. In both γδ T-APCs and moDCs, internalized antigen was transported across insulin-regulated aminopeptidase (IRAP)-positive early and late endosomes; however, and in contrast to various human DC subsets, γδ T-APCs efficiently translocated soluble antigen into the cytosol for processing via the cytosolic proteasome-dependent cross-presentation pathway. Of note, γδ T-APCs cross-presented influenza antigen derived from virus-infected cells and from free virus particles. The robust cross-presentation capability appears to be a hallmark of γδ T-APCs and underscores their potential application in cellular immunotherapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 1Present address: Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia. Author contributions: S.M., M.E., and B.M. designed research; S.M. and M.E. performed research; S.M., M.E., and B.M. analyzed data; and S.M., M.E., and B.M. wrote the paper. Edited* by Peter Cresswell, Yale University School of Medicine, New Haven, CT, and approved March 30, 2010 (received for review March 3, 2010) |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.1002769107 |